Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/203664
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumors |
Autor: | Nieto, Celia; Centa, Ariana; Rodríguez-Rodríguez, Jesús A.; Pandiella, Atanasio CSIC ORCID CVN ; Martín del Valle, Eva María | Palabras clave: | Targeted nanoparticles Paclitaxel Trastuzumab HER2-specificity Sodium alginate Piperazine |
Fecha de publicación: | 2019 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | Nanomaterials 9(7): 948 (2019) | Resumen: | Paclitaxel is one of the most widely used chemotherapeutic agents thanks to its effectiveness and broad spectrum of antitumor activity. However, it has a very poor aqueous solubility and a limited specificity. To solve these handicaps, a novel paclitaxel-trastuzumab targeted transport nanosystem has been developed and characterized in this work to specifically treat cancer cells that overexpress the human epidermal growth factor receptor-2 (HER2). Methods: Alginate and piperazine nanoparticles were synthetized and conjugated with paclitaxel:β-cyclodextrins complexes and trastuzumab. Conjugated nanoparticles (300 nm) were characterized and their internalization in HER2-overexpressing tumor cells was analyzed by immunofluorescence. Its specific antitumor activity was studied in vitro using human cell lines with different levels of HER2-expression. Results: In comparison with free paclitaxel:β-cyclodextrins complexes, the developed conjugated nanovehicle presented specificity for the treatment of HER2-overpressing cells, in which it was internalized by endocytosis. Conclusions: It seems that potentially avoiding the conventional adverse effects of paclitaxel treatment could be possible with the use of the proposed mixed nanovehicle, which improves its bioavailability and targets HER2-positive cancer cells. | Descripción: | © 2019 by the authors. | Versión del editor: | http://dx.doi.org/10.3390/nano9070948 | URI: | http://hdl.handle.net/10261/203664 | DOI: | 10.3390/nano9070948 | ISSN: | 2079-4991 | E-ISSN: | 2079-4991 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Paclitaxel_Trastuzumab_Nieto_Art2019.pdf | 1,83 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
6
checked on 28-abr-2024
SCOPUSTM
Citations
11
checked on 17-may-2024
WEB OF SCIENCETM
Citations
11
checked on 29-feb-2024
Page view(s)
128
checked on 21-may-2024
Download(s)
105
checked on 21-may-2024